[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356154-105":59,"doc-detail-356154-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","circulating-tumor-associated-autoantibody-signatures-for-diagnosis-and-prognosis-in-small-cell-lung-cancer-and-lung-adenocarcinoma","Circulating tumor-associated autoantibody signatures for diagnosis and prognosis in small-cell lung cancer and lung adenocarcinoma","","Tumour-associated autoantibodies (TAAbs) are investigated as biomarkers for lung cancer detection and outcome prediction, focusing on small-cell lung cancer (SCLC) and lung adenocarcinoma (LUAD). Serum from 695 individuals was profiled using protein-array screening followed by two-stage ELISA validation, and diagnostic models were benchmarked against conventional tumour markers. Six SCLC TAAbs and four LUAD TAAbs achieved AUC > 0.8 and outperformed ProGRP and CEA. TAAb induction related to antigen overexpression, somatic mutations and HLA class II polymorphisms, while seropositivity linked to age and advanced stage, showing subtype-specific survival effects and up to 2-year prediagnostic detectability.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/circulating-tumor-associated-autoantibody-signatures-for-diagnosis-and-prognosis-in-small-cell-lung-cancer-and-lung-adenocarcinoma/356154/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/circulating-tumor-associated-autoantibody-signatures-for-diagnosis-and-prognosis-in-small-cell-lung-cancer-and-lung-adenocarcinoma/356154.png","ImageObject",300,407,{"name":92,"@type":93},"anakgang17","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"How were TAAb signatures identified and validated in this study?","Question",{"text":113,"@type":114},"Serum from 695 individuals was first analysed by protein-array screening, and then key TAAbs were validated using a two-stage ELISA approach.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What diagnostic performance did the identified TAAb panels achieve?",{"text":118,"@type":114},"Six TAAbs for SCLC and four for LUAD produced strong diagnostic performance with AUC values above 0.8 and outperformed ProGRP and CEA.",{"name":120,"@type":111,"acceptedAnswer":121},"How do TAAb seropositivity and concentrations relate to prognosis and early detection?",{"text":122,"@type":114},"TAAb panel seropositivity associated with older age and advanced stage; it predicted poor survival in SCLC but a favourable outcome in advanced LUAD. In prediagnostic sera, TAAb concentrations increased progressively and were detectable up to 2 years before clinical diagnosis.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356154,1790244158,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www.nature.com/bjc](www.nature.com/bjc British)[ British](www.nature.com/bjc British) Journal of Cancer  \nARTICLE OPEN   \nMolecular Diagnostics  \nCirculating tumor-associated autoantibody signatures for diagnosis and prognosis in small-cell lung cancer and lung adenocarcinoma  \nChaoqi Liu1, Eriko Fukuda2, Yoji Sagiya 1, Hiromi Tsuru3, Yuka Okamoto3, Takayuki Morisaki 1,3, Yoichiro Kamatani4,  \nYukinori Okada 5,6,7,8, Yutaka Suzuki9, Akinori Kanai 9, Naoki Goshima10, Chizu Tanikawa1 ✉, Koichi Matsuda 1,3 ✉ and the BioBank Japan Project*  \n© The Author(s) 2026  \nBACKGROUND: Tumour-associated autoantibodies (TAAbs) are promising biomarkers for cancer detection, but their induction and clinical relevance in lung cancer remain unclear.  \nMETHODS: Serum samples from 695 individuals were analysed for TAAb proﬁling by protein-array screening and two-stage ELISA validation. Diagnostic models were constructed with identiﬁed TAAbs and compared with conventional tumour markers. Potential mechanisms, clinical and prognostic features of TAAb seropositivity were analysed and its presence in prediagnostic sera was evaluated to assess the potential for early detection.  \nRESULTS: Six TAAbs for small cell lung cancer (SCLC) and four for lung adenocarcinoma (LUAD) were identiﬁed, demonstrating excellent diagnostic performance (AUC > 0.8) and outperforming ProGRP and CEA. TAAb induction correlated with antigen overexpression, somatic mutations and HLA class II amino acid polymorphisms. TAAb panel seropositivity was associated with older age and advanced stage in both subtypes, and predicted poor survival in SCLC but a favourable outcome in advanced LUAD. In prediagnostic sera, the TAAb concentration increased progressively, with detectability up to 2 years before clinical diagnosis. CONCLUSIONS: Distinct TAAb panels were identiﬁed for SCLC and LUAD, serving as accurate diagnostic markers that enable early detection and as indicators of prognosis in different clinical contexts.  \nBritish Journal of Cancer (2026) 135:992–1005; [https://doi.org/10.1038/s41416-026-03504-z](https://doi.org/10.1038/s41416-026-03504-z)  \nBACKGROUND  \nLung cancer has the highest global burden in terms of incidence and cancer-related mortality. In 2022, it caused over 2.48 million new cases and 1.81 million deaths, representing 12.4% of all new cancers and 18.7% of cancer-related deaths [1] . Lung adenocarcinoma (LUAD) is the most common subtype, accounting for approximately 39% of newly diagnosed lung cancer cases in males and 57% in females [2] . Small cell lung cancer (SCLC), a highly aggressive neuroendocrine malignancy, accounts for approximately 10–15% of all lung cancers [2, 3] . In LUAD, the 5-year relative survival rate is 73.7% for localised disease but decreases to 13.2% in distant stages [4] . Similarly, in SCLC, the  \n5-year survival rate is 60% for stage I and 42% for stage II, compared with 19% for stage III and 3% for stage IV [5], underscoring the importance of early diagnosis. Low-dose CT screening has been shown to reduce lung cancer-related mortality by 20% after three rounds of screening [6] and is recommended for high-risk individuals deﬁned by age and smoking history. However, these criteria may exclude many atrisk individuals [6] . Moreover, low-dose CT screening has been associated with substantial healthcare costs, including an additional cost of $1631 per person compared with no screening [7], as well as a high false-positive rate and unnecessary follow-up procedures [8, 9] . Therefore, minimally invasive, cost-effective  \n1Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. 2Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Ibaraki, Japan. 3Laboratory of Genome Technology, Human Genome Center, Institute of Medical Science, The University of T","cbCaiq1Qi5kd4cRp","https://ap.wps.com/l/cbCaiq1Qi5kd4cRp","pdf",7525514,14,"English","# Background\n## Lung cancer burden and need for early diagnosis\n# Methods\n## Serum profiling and validation workflow\n## Construction and comparison of diagnostic models\n# Results\n## Identified TAAb signatures for SCLC and LUAD\n## Links to antigen biology and clinical features\n## Prognostic associations and prediagnostic detection\n# Conclusions","[{\"question\":\"How were TAAb signatures identified and validated in this study?\",\"answer\":\"Serum from 695 individuals was first analysed by protein-array screening, and then key TAAbs were validated using a two-stage ELISA approach.\"},{\"question\":\"What diagnostic performance did the identified TAAb panels achieve?\",\"answer\":\"Six TAAbs for SCLC and four for LUAD produced strong diagnostic performance with AUC values above 0.8 and outperformed ProGRP and CEA.\"},{\"question\":\"How do TAAb seropositivity and concentrations relate to prognosis and early detection?\",\"answer\":\"TAAb panel seropositivity associated with older age and advanced stage; it predicted poor survival in SCLC but a favourable outcome in advanced LUAD. In prediagnostic sera, TAAb concentrations increased progressively and were detectable up to 2 years before clinical diagnosis.\"}]","Circulating tumor-associated autoantibody signatures for diagnosis and prognosis in small-cell lung cancer and lung adenocarcinoma | PDF",1790123689,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4375fb74de8ba460f72c9e47c5c702b.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14ce97d289323f35edc2ccd531be1096.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/13395b65e143a4391251b372b894b32f.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/960895144f3a02d74c049f32141fafb3.webp",980,1301]